| Symbol | MDGL |
|---|---|
| Name | MADRIGAL PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 200 BARR HARBOR DRIVE,SUITE 200, FOUR TOWER BRIDGE, WEST CONSHOHOCKEN, Pennsylvania, 19428, United States |
| Telephone | +1 267 824-2827 |
| Fax | — |
| — | |
| Website | https://www.madrigalpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001157601 |
| Description | Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. Additional info from NASDAQ: |
Ribo und Madrigal erreichen ersten wichtigen Meilenstein bei der Weiterentwicklung neuartiger siRNA-Therapien für MASH
Read moreRibo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASH
Read moreRibo et Madrigal franchissent une première étape majeure dans le développement de nouvelles thérapies à base dARNsi pour la stéatohépatite associée à un dysfonctionnement métabolique (MASH)
Read moreRibo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
Read moreMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Read more(99% Neutral) MADRIGAL PHARMACEUTICALS, INC. (MDGL) Announces Director Election
Read moreNew Form S-8 - MADRIGAL PHARMACEUTICALS, INC. <b>Filed:</b> 2026-06-17 <b>AccNo:</b> 0001104659-26-075183 <b>Size:</b> 574 KB
Read moreMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Read moreSoergel David 🔴 sold 1.0K shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at $495.74 Transaction Date: Jun 01, 2026 | Filing ID: 039653
Read moreDirector Levy Richard S 🔴 sold 5.7K shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at $519.98 ($2.9M) Transaction Date: May 22, 2026 | Filing ID: 037830
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07541469 | Rezdiffra Pregnancy and Lactation Registry | — | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Recruiting | 2026-03-04 | 2030-04-08 | ClinicalTrials.gov |
| NCT07335601 | Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH | Phase2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Recruiting | 2025-12-29 | 2029-03-01 | ClinicalTrials.gov |
| NCT06397872 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple … | Phase1 | Renal Impairment | Completed | 2024-03-06 | 2024-12-31 | ClinicalTrials.gov |
| NCT05500222 | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Pa… | Phase3 | NASH | Active_Not_Recruiting | 2022-08-26 | 2027-01-01 | ClinicalTrials.gov |
| NCT04951219 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in P… | Phase3 | Non-Alcoholic Fatty Liver Disease | Active_Not_Recruiting | 2021-07-09 | 2027-04-01 | ClinicalTrials.gov |
| NCT04197479 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in N… | Phase3 | Non-Alcoholic Fatty Liver Disease | Completed | 2019-12-16 | 2023-01-06 | ClinicalTrials.gov |
| NCT04671069 | Drug Interaction Study of MGL-3196 With Clopidogrel | Phase1 | Healthy | Completed | 2019-07-26 | 2019-09-14 | ClinicalTrials.gov |
| NCT03900429 | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in… | Phase3 | NASH - Nonalcoholic Steatohepatitis | Active_Not_Recruiting | 2019-03-28 | 2028-01-01 | ClinicalTrials.gov |
| NCT04671056 | Drug Interaction Study of MGL-3196 With Pioglitazone | Phase1 | Healthy | Completed | 2018-11-09 | 2019-01-05 | ClinicalTrials.gov |
| NCT04643795 | Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mul… | Phase1 | Hepatic Impairment | Completed | 2018-10-25 | 2021-08-04 | ClinicalTrials.gov |
| NCT03413124 | Bioavailability Study of MGL-3196 Tablets Compared to Capsules | Phase1 | Healthy | Completed | 2018-02-05 | 2018-03-13 | ClinicalTrials.gov |
| NCT03220165 | Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196 | Phase1 | Healthy | Completed | 2017-08-06 | 2017-09-03 | ClinicalTrials.gov |
| NCT03038022 | Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (… | Phase2 | Heterozygous Familial Hypercholesterolemia | Completed | 2017-02-23 | 2018-01-15 | ClinicalTrials.gov |
| NCT02912260 | Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) | Phase2 | Non-alcoholic Steatohepatitis | Completed | 2016-10-18 | 2021-11-23 | ClinicalTrials.gov |
| NCT02749578 | Drug Interaction Study of MGL-3196 With Atorvastatin | Phase1 | Healthy | Completed | 2016-04-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02542969 | Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin | Phase1 | Healthy | Completed | 2015-09-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01519531 | Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects | Phase1 | Drug Safety | Completed | 2012-01-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01367873 | Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects | Phase1 | Drug Safety | Completed | 2011-06-01 | 2011-10-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Placebo | Other | Phase PHASE2 | Heterozygous Familial Hypercholesterolemia | COMPLETED | NCT03038022 |
| MGL-3196 (resmetirom) | Other | Phase PHASE2 | Heterozygous Familial Hypercholesterolemia | COMPLETED | NCT03038022 |
| Placebo | Other | Phase PHASE3 | NASH | ACTIVE_NOT_RECRUITING | NCT05500222 |
| Resmetirom | Other | Phase PHASE3 | NASH | ACTIVE_NOT_RECRUITING | NCT05500222 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE3 | Non-Alcoholic Fatty Liver Disease | ACTIVE_NOT_RECRUITING | NCT04951219 |
| Resmetirom | Other | Phase PHASE3 | Non-Alcoholic Fatty Liver Disease | ACTIVE_NOT_RECRUITING | NCT04951219 |
| Resmetirom | Other | Phase PHASE3 | Non-Alcoholic Fatty Liver Disease | ACTIVE_NOT_RECRUITING | NCT04951219 |
| Resmetirom | Other | Phase PHASE3 | Non-Alcoholic Fatty Liver Disease | ACTIVE_NOT_RECRUITING | NCT04951219 |
| Resmetirom | Other | Phase PHASE3 | Non-Alcoholic Fatty Liver Disease | ACTIVE_NOT_RECRUITING | NCT04951219 |
| Resmetirom | Other | Phase PHASE3 | Non-Alcoholic Fatty Liver Disease | ACTIVE_NOT_RECRUITING | NCT04951219 |
| Resmetirom | Other | Phase PHASE3 | Non-Alcoholic Fatty Liver Disease | ACTIVE_NOT_RECRUITING | NCT04951219 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| VIA-3196 | Other | Phase PHASE1 | Drug Safety | COMPLETED | NCT01519531 |
| Placebo | Other | Phase PHASE1 | Drug Safety | COMPLETED | NCT01519531 |
| MGL-3196 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02749578 |
| Atorvastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02749578 |
| MGL-3196 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03220165 |
| MGL-3196 Capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03413124 |
| MGL-3196 Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03413124 |
| Pioglitazone 15mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04671056 |
| MGL-3196 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04671056 |
| Clopidogrel | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04671069 |
| MGL-3196 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04671069 |
| MGL-3196 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02542969 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02542969 |
| Simvastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02542969 |
| VIA-3196 | Other | Phase PHASE1 | Drug Safety | COMPLETED | NCT01367873 |
| Placebo | Other | Phase PHASE1 | Drug Safety | COMPLETED | NCT01367873 |
| Resmetirom | Other | Phase PHASE3 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT04197479 |
| Placebo | Other | Phase PHASE3 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT04197479 |
| MGL-3196 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT04643795 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH | ACTIVE_NOT_RECRUITING | NCT05500222 |
| Resmetirom | Other | Phase PHASE3 | NASH | ACTIVE_NOT_RECRUITING | NCT05500222 |
| Resmetirom | Other | Phase PHASE3 | Non-Alcoholic Fatty Liver Disease | ACTIVE_NOT_RECRUITING | NCT04951219 |
| 100 mg Resmetirom Tablet | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT06397872 |
| Placebo | Other | Phase PHASE2 | Heterozygous Familial Hypercholesterolemia | COMPLETED | NCT03038022 |
| MGL-3196 (resmetirom) | Other | Phase PHASE2 | Heterozygous Familial Hypercholesterolemia | COMPLETED | NCT03038022 |
| Placebo | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT02912260 |
| MGL-3196 | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT02912260 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| 100 mg Resmetirom Tablet | DRUG | Phase PHASE1 | Renal Impairment | COMPLETED | NCT06397872 |
| Clopidogrel | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04671069 |
| Pioglitazone 15mg | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04671056 |
| Resmetirom | DRUG | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT07335601 |
| Liver Biopsy | PROCEDURE | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 Capsule | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03413124 |
| MGL-3196 Tablet | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03413124 |
| MGL-3196 (resmetirom) | DRUG | Phase PHASE2 | Heterozygous Familial Hypercholesterolemia | COMPLETED | NCT03038022 |
| Atorvastatin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02749578 |
| MGL-3196 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04671069 |
| Rosuvastatin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02542969 |
| Simvastatin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02542969 |
| VIA-3196 | DRUG | Phase PHASE1 | Drug Safety | COMPLETED | NCT01519531 |
| Placebo | DRUG | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT07335601 |